Results 161 to 170 of about 19,656 (270)

Reviving of Coenonympha oedippus: A comprehensive approach to the reintroduction of an endangered European butterfly

open access: yesInsect Conservation and Diversity, EarlyView.
The reintroduction of the endangered butterfly Coenonympha oedippus is the first conservation translocation of an invertebrate species in Slovenia. Three years after reintroduction, the population showed an 87% growth rate, demonstrating the effectiveness of the selected reintroduction site and its management, the source individuals and the protocols ...
Tatjana Čelik   +4 more
wiley   +1 more source

A systematic review and meta‐analysis on urban arthropod diversity

open access: yesInsect Conservation and Diversity, EarlyView.
Our results evidence that urbanization is associated with a lower mean diversity of arthropods. We also detected a higher variance of arthropod diversity in urban than in rural habitats. Reported data suggest that cities hold a great potential for arthropod conservation if adequate measures are implemented. Abstract Urbanization is rapidly expanding at
Olivia Sanllorente   +3 more
wiley   +1 more source

The salivary gland transcriptome of Varroa destructor reveals suitable targets for RNAi‐based mite control

open access: yesInsect Molecular Biology, EarlyView.
RNAseq and differential expression analysis identified 15 salivary gland genes encoding secreted proteins with putative anti‐bacterial, anti‐fungal, cytolytic, digestive and immunosuppressive function. The three most highly transcribed genes were selected to study their functional importance by reverse genetics, using a non‐invasive approach of dsRNA ...
Andrea Becchimanzi   +9 more
wiley   +1 more source

European Guideline (EuroGuiDerm) on atopic eczema: Living update

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
The updated guideline includes a new evidence‐based recommendation for the IL‐13 inhibitor lebrikizumab. In addition, the Janus kinase inhibitors baricitinib and abrocitinib, which were initially only approved for adult patients, are now also recommended for children from the age of 2 and adolescents from the age of 12, respectively.
A. Wollenberg   +31 more
wiley   +1 more source

Home - About - Disclaimer - Privacy